<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729595</url>
  </required_header>
  <id_info>
    <org_study_id>APC400-03</org_study_id>
    <nct_id>NCT04729595</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.</brief_title>
  <official_title>A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adamis Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adamis Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of&#xD;
      Tempol in subjects with COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2/3 Adaptive, Randomized, Double-blind, placebo-controlled enrolling high risk subjects&#xD;
      with early COVID19 infection with a primary endpoint of limiting hospitalization.&#xD;
&#xD;
      As part of the initial phase 2 portion of the study, 50 COVID positive subjects with&#xD;
      comorbidities will be enrolled. Eligible subjects positively diagnosed COVID-19 infection&#xD;
      will be randomized 1:1 to receive either Tempol or placebo.&#xD;
&#xD;
      An interim analysis by a DSMB will examine safety and markers of systemic inflammation during&#xD;
      a Stage 1 interim analysis. Based on the DSMB adjudication, the Phase 3 portion of the trial&#xD;
      will begin with a second interim analysis after enrollment of 124 subjects&#xD;
&#xD;
      This protocol will seek to enroll approximately 248 subjects &gt; 18 years of age diagnosed with&#xD;
      COVID-19 infection. All subjects will receive standard of care. As standard of care can vary&#xD;
      between institution over time for the treatment of COVID-19; Off label medication use,&#xD;
      therapies, devices, and interventions used in standard of care practice for COVID-19 is&#xD;
      allowed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-blind, placebo-controlled enrolling high risk subjects with early COVID19 infection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized, Double-blind, Placebo-Controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure</measure>
    <time_frame>21 Days from the date Randomization/First Dosing.</time_frame>
    <description>The rate of hospitalization in the treated (Tempol) vs. placebo participant population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measure</measure>
    <time_frame>28 Days from Randomization/First Dosing</time_frame>
    <description>Time sustained clinical resolution of COVID-19 symptoms in the treated (Tempol) vs. placebo participant population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tempol (MMB-02) 800 mg per Day (n=124)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (n=124)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tempol</intervention_name>
    <description>Tempol 800 mg capsule will be administered at 400mg (2 capsules) two times daily for fourteen (14) consecutive days.</description>
    <arm_group_label>Active Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will be administered orally (2 capsules) two times daily for fourteen (14) consecutive days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects 18 years of age and older with at least one comorbidity (i.e., hypertension,&#xD;
             diabetes, obesity, cancer, chronic renal disease, immunodeficiency and in the opinion&#xD;
             of the investigator the comorbidity is not acutely life-threatening).&#xD;
&#xD;
          -  Laboratory confirmed infection of SAR-COV-2 within 5 days of Baseline/Day 1.&#xD;
&#xD;
          -  Subjects must meet the severity score of Moderate or greater for two of the first ten&#xD;
             symptoms listed in the Patient Reported Outcomes (PRO) at screening.&#xD;
&#xD;
          -  Ability to travel to clinic.&#xD;
&#xD;
          -  Ability to understand and sign an informed consent form.&#xD;
&#xD;
          -  Female subjects of child-bearing potential who are capable of conception must be:&#xD;
             post- menopausal (one year or greater without menses), surgically incapable of&#xD;
             childbearing, or practicing two effective methods of birth control. Acceptable methods&#xD;
             include abstinence, intrauterine device, spermicide, barrier, male partner surgical&#xD;
             sterilization and hormonal contraception. A female subject â‰¥18 years of age and of&#xD;
             child bearing potential must agree to practice two acceptable methods of birth control&#xD;
             during the study period.&#xD;
&#xD;
          -  Ability to swallow a capsule.&#xD;
&#xD;
          -  Ability to complete an electronic diary via smartphone or web.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for hospitalization based on severe or critical symptoms based on CDC guidance.&#xD;
&#xD;
          -  Subject in long-term care facility.&#xD;
&#xD;
          -  Known hypersensitivity or contra-indication to Tempol.&#xD;
&#xD;
          -  In the opinion of the investigator, any reason that would make the follow up of the&#xD;
             subject impossible during the study treatment and follow up period. Any reason the&#xD;
             subject cannot comply with study and study procedures.&#xD;
&#xD;
          -  Subjects receiving any other investigational agent within 4 weeks od Baseline/Day 1.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Evidence of any known chronic liver or kidney disease.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73m2 within 14 days of&#xD;
             Baseline.&#xD;
&#xD;
          -  Serum AST/ALT/Total bilirubin levels greater than 2 times upper limit of normal within&#xD;
             14 days of baseline.&#xD;
&#xD;
          -  Prior COVID-19 vaccination or prior recovery from documented COVID-19 infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald B Moss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Adamis Pharmaceutical Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronald B Moss, MD</last_name>
    <phone>619-742-6035</phone>
    <email>rmoss@adamispharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Doral medical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Diaz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elias Sarkis, MD</last_name>
      <phone>352-333-0094</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omega Research Orlando, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwabena Ayesu, MD</last_name>
      <phone>407-512-1054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMA Clinical Research, PC</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Chipman, MD</last_name>
      <phone>407-288-6516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research GI, LLC.</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adil Fatakia, MD</last_name>
      <phone>504-371-3808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMA Clinical Research, PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Miller, MD</last_name>
      <phone>314-367-0777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monroe Biomedical Research</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Awawu Igbinadolor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center of Middle Tennessee, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Slandzicki, MD</last_name>
      <phone>615-716-1050</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tempol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

